-+ 0.00%
-+ 0.00%
-+ 0.00%

First Berlin keeps Jaguar Health rating under review, price target under review

PUBT·08/28/2026 12:44:39
Listen to the news
First Berlin keeps Jaguar Health rating under review, price target under review
  • First Berlin Equity Research kept its “Under Review” recommendation on Jaguar Health in an update.
  • Q2 2026 product revenue fell to USD 1.2 million from USD 2.9 million, reflecting the Future Pak licensing shift to cost-plus supply.
  • OpEx declined to USD 8.8 million from USD 11 million, narrowing the operating loss to USD 7.6 million from USD 8 million.
  • Notes payable dropped to USD 15.6 million at June 30 from USD 42.5 million at year-end 2025, turning equity to USD 4.9 million.
  • Key pressure points flagged: USD 1.5 million monthly minimum royalties restarting in October 2026, USD 6.6 million secured note maturity, USD 40 million ELOC backstop.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via EQS News (Ref. ID: rc_26666) on August 28, 2026, and is solely responsible for the information contained therein.